Corporate hospital stocks came under pressure on September 30 after strong observations from the Supreme Court regarding the prices patients are charged for medicines.

Shares of several major hospital companies fell sharply during morning trading, with some stocks declining by around 4–6%. The broader healthcare sector was also affected as investors assessed the possibility that tighter rules on medicine margins could impact hospital revenues and profitability.

Why did hospital stocks fall?

The Supreme Court was hearing a matter concerning drug pricing when the bench expressed serious concern about the margins being charged by hospitals on medicines.

The court particularly questioned situations where patients are required to purchase medicines from a hospital's own pharmacy instead of being allowed to obtain them elsewhere.

During the hearing, the bench referred to an example in which a cancer medicine costing around ₹2,700 was allegedly being sold to a patient for approximately ₹27,000.

The court strongly criticised such practices and questioned whether a reasonable limit should be placed on medicine margins.

Supreme Court discusses a 16% margin

One of the key points raised during the hearing was whether a uniform 16% margin on medicines could be considered.

The court questioned why such a limit could not apply across medicines rather than creating separate treatment for essential and non-essential drugs.

Solicitor General Tushar Mehta acknowledged the seriousness of the issue and indicated that the matter would be discussed with the concerned authorities.

However, it is important to note that the 16% margin is currently a suggestion raised during the proceedings. It is not a final rule or order.

Which hospital stocks were affected?

The comments triggered selling across several listed hospital companies.

During morning trading, shares of companies including Apollo Hospitals, Yatharth Hospital, Max Healthcare, Fortis Healthcare, KIMS and Aster DM came under pressure.

The broader healthcare sector also weakened, with the Nifty Pharma and BSE Healthcare indices declining during the session.

The market reaction reflects investor concerns that restrictions on medicine margins could affect the profitability of hospitals that generate a significant portion of their revenue from pharmacy operations.

Why are medicine margins important for hospitals?

Medicines and medical devices can represent a significant portion of hospital revenue.

According to market analysts cited in the report, they can account for roughly 20–35% of hospital revenue in some cases.

If hospitals were required to operate with a much lower margin on medicines, the impact could be significant for companies that rely heavily on pharmacy income.

Hospitals with large retail pharmacy networks could potentially face greater pressure than businesses whose revenues are more heavily driven by clinical services.

Apollo could face greater impact

Market analysts believe hospital groups with substantial pharmacy operations could be more exposed if a strict medicine-margin cap is introduced.

Apollo Hospitals could potentially see a comparatively larger impact because of its extensive pharmacy network.

Other large hospital chains such as Max Healthcare, Aster DM, Medanta and Fortis could also be affected depending on how any eventual regulations are structured.

On the other hand, hospital groups with a greater dependence on clinical services rather than pharmacy operations may see a relatively smaller impact.

But there is no final decision yet

Despite the sharp market reaction, investors should keep one point in mind: the Supreme Court has not imposed a 16% medicine-margin cap through the hearing described above.

The discussion is still part of an ongoing legal process, and the government has been asked to consider the issue.

Any eventual regulation could also differ from the proposal discussed during the hearing.

The next hearing is scheduled for October 12, 2026. Until then, the market is likely to remain sensitive to developments surrounding medicine pricing and hospital pharmacy margins.

What could happen to patients?

If a uniform cap on medicine margins is eventually introduced, it could potentially reduce the amount patients pay for medicines purchased through hospitals.

However, the ultimate impact would depend on the details of any policy, including which medicines and products are covered and how hospitals are permitted to recover their operating costs.

For investors, the key issue is how much such a change could affect hospital revenue and profitability. For patients, the bigger question is whether the eventual policy can make expensive treatment more affordable without affecting the availability and quality of healthcare services.